Skip to main content

FDA Approvals: Once-Weekly Exenatide for Type 2 Diabetes

Clinical Context

The US Food and Drug Administration (FDA) has approved an extended-release formulation of exenatide injection as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. This is the first approved medication administered once weekly for type 2 diabetes.
The FDA has required the manufacturer to perform a randomized, double-blind, placebo-controlled trial of effects of the drug on the incidence of major adverse cardiovascular events, pancreatic cancer, kidney disease, serious hypoglycemia, and on potential biomarkers of medullary thyroid carcinoma (MTC). An MTC case series registry and Risk Evaluation and Mitigation Strategy (REMS) are also mandated.

Study Synopsis and Perspective

The US FDA approved a once-weekly extended-release formulation of exenatide injection (Bydureon, Amylin Pharmaceuticals) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
It is the first once-a-week medication for type 2 diabetes on the market.
The approval comes roughly 2 and a half years after Amylin applied for FDA approval of the extended-release version of its twice-daily exenatide injection (Byetta). During that time, the manufacturer endured 2 rejections, with the agency asking it to supply more data on efficacy and safety — in particular, the drug's effect on heart rate.
The agency still has its safety concerns. In approving the once-weekly medication, the FDA ordered Amylin to conduct a randomized, double-blind, placebo- controlled trial evaluating the drug's effect on the incidence of major adverse cardiovascular events among patients with type 2 diabetes. The trial also must assess the risk for certain other adverse events, such as pancreatic cancer, renal disorders, and serious hypoglycemia, and the long-term effects on potential biomarkers of MTC.
In addition, the company must conduct a number of studies with mice — and one that also includes mice, rat, and human thyroid C cells — that focus on MTC.
Two other precautionary strings are attached to the drug's approval. The FDA required Amylin to create an MTC case series registry to monitor the annual incidence of the cancer in the United States for at least 15 years and identify any increase related to the introduction of extended-release exenatide. And Amylin must carry out a risk evaluation and mitigation strategy (REMS) "to ensure the benefits of the drug outweigh the risks of [MTC] and acute pancreatitis, including hemorrhagic and necrotizing pancreatitis."
A boxed warning on the drug's label explains why the FDA is worried about MTC. Extended-release exenatide "causes thyroid C-cell tumors at clinically relevant exposures in rats," according to the boxed warning. "It is unknown whether Bydureon causes thyroid C-cell tumors, including ...MTC, in humans, as human relevance could not be determined by clinical or nonclinical studies."
The boxed warning also states that the drug is contraindicated in patients with a personal or family history of MTC and in patients with multiple endocrine neoplasia syndrome type 2.
Extended-Release Exenatide Outperforms Twice-Daily Version
A clinical trial showed that after 24 weeks of treatment, patients taking extended-release exenatide lowered their hemoglobin A1c levels by 1.6 percentage points from baseline compared with a 0.9-percentage point reduction for patients taking the twice-daily version, Amylin stated in a press release.
The most common adverse effects that emerged in clinical trials were nausea (which usually decreased with time), hypoglycemia, vomiting, diarrhea, jittery feeling, dizziness, headache, dyspepsia, constipation, and asthenia.
Amylin stated that its newly approved drug will be available in pharmacies in February.
Other Warnings, Precautions, and Adverse Reactions
Postmarketing reports with exenatide indicate some cases of fatal and nonfatal hemorrhagic or necrotizing pancreatitis. If pancreatitis is suspected, exenatide should be discontinued, and it should not be restarted if pancreatitis is confirmed.
There is an increased risk for hypoglycemia when extended-release exenatide is used in combination with a sulfonylurea. In these cases, clinicians should consider reducing the sulfonylurea dose.
There have been some postmarketing reports of renal impairment with exenatide, sometimes requiring hemodialysis and kidney transplantation. Use of the drug is not recommended in patients with severe renal impairment or end-stage renal disease, and caution is warranted in patients with renal transplantation or moderate renal impairment.
Extended-release exenatide is not recommended in patients with gastroparesis or other severe gastrointestinal tract disease.
Patients in whom serious hypersensitivity reactions develop should discontinue extended-release exenatide and other suspect medications and promptly seek medical attention.
Nausea, diarrhea, headache, vomiting, constipation, injection site itching or nodule, and dyspepsia are the most common adverse reactions, occurring in at least 5% of patients and more often than with the comparator in clinical trials.
Limitations of Use
Because of the uncertain relevance of the rat thyroid C-cell tumor findings to humans, clinicians should prescribe extended-release exenatide only to patients in whom the potential benefits are thought to outweigh the potential risk.
It should not be used first-line in patients who have inadequate glycemic control with diet and exercise, nor is it a substitute for insulin. Also, it is ineffective in patients with type 1 diabetes and in patients with diabetic ketoacidosis. Concurrent use with insulin has not been studied and cannot be recommended, nor should it be used with exenatide injection.
Other antidiabetic agents should be considered in patients with a history of pancreatitis.
Use in Special Populations
Animal data suggest that extended-release exenatide may cause fetal harm, and it should therefore be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Caution is warranted when the drug is given to a breast-feeding mother.
More information about the approval of extended-release exenatide is available at the FDA Web site.
Laurie Barclay, MD, contributed to this synopsis.

Clinical Implications


  • The FDA has approved a once-weekly extended-release formulation of exenatide injection to improve glycemic control in adults with type 2 diabetes, used as an adjunct to diet and exercise.
  • Exenatide has been linked to some cases of fatal and nonfatal hemorrhagic or necrotizing pancreatitis. The risk for hypoglycemia is increased when extended-release exenatide is used concurrently with a sulfonylurea. The drug is not recommended in patients with severe renal impairment or end-stage renal disease and is not recommended in patients with gastroparesis or other severe gastrointestinal tract disease.
  • Clinicians should prescribe extended-release exenatide only to patients in whom the potential benefits are thought to outweigh the potential risk, because it is unclear whether findings of thyroid C-cell tumors in rats are relevant to humans. It is not intended as first-line therapy in patients who have inadequate glycemic control with diet and exercise, is not a substitute for insulin, and is not effective in patients with type 1 diabetes. In patients with a history of pancreatitis, other antidiabetic agents should be considered.

Comments

Post a Comment

Popular posts from this blog

Missing Data Lead FDA Panel to Vote Against Rivaroxaban for ACS May 23, 2012 (Updated May 24, 2012) (Silver Spring, Maryland) — The missing data issues plaguing the ATLAS ACS 2 TIMI 51 trial of the factor Xa inhibitor rivaroxaban (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the FDA Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting, the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus clopidogrel, or ticlopidine. Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the ATLAS ACS TIMI 46 phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the risk of bleeding and intracranial hemorrhage, but the studies were hindered by early patient withdrawals and missing data. We Don't Know What We're Missing Based on the ATLAS ACS 2 results, FDA reviewer Dr Karen Hicks recommended approval of rivaroxaban for the requested indications except all-cause mortality. However, another FDA reviewer, Dr Thomas Marciniak, was adamant that the trial results are not interpretable because about 12% of the patients had incomplete follow-up, far higher than the 1% to 1.5% differences in the end-point rates between rivaroxaban and placebo. A total of 1294 subjects discontinued the trial prematurely, and the company was only able to contact 183, of which 177 were confirmed to be alive. Because of the patient dropouts, the company adopted a "modified intention-to-treat analysis," whereby patients were observed for 30 days after randomization or the global end date for the trial, instead of observing all the patients until the end of the trial as the FDA originally suggested. Marciniak criticized the sponsor's efforts to follow the patients and said that three patient deaths not counted in the modified intention-to-treat analysis may just be the "tip of the iceberg." Because the percentage of patients whose ultimate vital status remains unknown is much greater than the reported differences in mortality rates, the claimed mortality benefits are not reliable. The majority of the panel sided with Marciniak. For example, Dr Sanjay Kaul (University of California, Los Angeles) voted "no" because "there was enough uncertainty in the quality and robustness of the data that dissuaded me from voting yes. . . . The 'missingness' of the data doesn't invalidate it, but it certainly makes it hard to infer [the conclusion]." Dr Steven Nissen (Cleveland Clinic, OH) said that the decision to use the modified intention-to-treat analysis had a "profound impact" on the interpretability of the data. "It's saying we don't care what happens after 30 days, [and] that colored the trial in ways we couldn't recover from." Given the risk of major bleeding, "I want to see better evidence that this strategy of adding an Xa inhibitor or a direct thrombin inhibitor or something else to a good antiplatelet agent is robustly better for the patient," Nissen said. He recommends that the companies run a new trial of the 2.5 twice-daily dose of rivaroxaban using a strict intention-to-treat approach, but, he said, "I don't expect the death benefit to be too robust." Several panelists said they were concerned that the patients who dropped out of the trial were disproportionately likely to have a bleeding event, which led them to quit the trial, or a "protopathic" event, as statistician Dr Scott Emerson (University of Washington, Seattle) put it. "We're worried that an impending event is what is changing their behavior. We see that all the time in clinical trials--that regularly measured end points do not pick up [all of] the events," he said. He said that since the company was only able to contact 183 of the over 1200 patients who dropped out, it is possible that the dropouts skew the outcomes comparison of the trial. "Differential event rates after dropout are the number-one thing we're afraid of, so you have to explore it" in a statistical sensitivity analysis of the potential impact of these unknown outcomes. "It would not surprise me if, at the end of the day, these data did not hold up under a proper sensitivity analysis," he said. "What I want to know is, among the people who had events, how differential was the follow-up, but I can tell you by just looking at it, there was a very slightly different amount of follow-up of the people in the treatment arm. But I don't know whether everyone in the treatment arm was cured and they were trekking in the Himalayas and everyone in the placebo arm went home to die. I don't know that that's not the case." Dr Maury Krantz (University of Colorado, Denver) voted in favor of approval but said he does not know how rivaroxaban would perform in general clinical practice, especially when used with aspirin and clopidogrel. "I felt very much torn by this. This isn't a simple paradigm shift. It means going to triple therapy, which is really a three-headed monster in many ways. I think that what you're going to see in practice, if this is not done carefully with the proper labeling and secondary studies, is really dramatic magnification of bleeding and perhaps minimization of the efficacy benefit."

May 23, 2012   (Updated May 24, 2012)  (Silver Spring, Maryland)  —  The missing data issues plaguing the  ATLAS ACS 2 TIMI 51   trial of the factor Xa inhibitor  rivaroxaban  (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the  FDA  Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting , the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus  clopidogrel , or  ticlopidine . Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the  ATLAS ACS TIMI 46   phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the ri...
Post a Comment
Read more

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...
Post a Comment
Read more

Sitting at Work Raises All-Cause and CV Mortality Risk

May 21, 2012 (Lyon, France) — Sitting at work raises the risk of dying from cardiovascular (CV) and metabolic diseases, as well as the risk of dying from all causes, regardless of any exercise in which the individual may engage. That was the finding of a study reported here at the 19th European Congress on Obesity (ECO) by Anne Grunseit, PhD, from the Prevention Research Collaboration in the School of Public Health at the University of Sydney, Australia, and Norwegian colleagues. Research is increasingly focusing on sedentary behavior with low energy expenditure, including sitting and lying down, as behavioral risk factors for obesity and chronic disease. Sitting occurs during travel, while watching television, using computers, and reading. But with people often spending at least 9 hours a day at work, with fewer than 20% of jobs requiring physical exertion, and with many people spending at least 4 hours a day sitting at work, the sedentary time at work is high, and many people ar...
Post a Comment
Read more